Hoberman Kenneth 4

What Happened
Kenneth Hoberman, a director of Nuvectis Pharma, was granted 35,000 restricted common shares (transaction code A) on 2026-06-11. The grant is recorded at $0 per share in the Form 4 (i.e., no cash purchase); total reported consideration = $0. This is a director compensation award rather than an open-market buy or sale.

Key Details

• Transaction date: 2026-06-11; Form 4 filed 2026-06-12 (timely filing).
• Amount: 35,000 restricted common shares granted at $0.00 per share.
• Vesting: Shares vest in equal annual installments over three years beginning on the first anniversary of the grant, subject to continued board service (Footnote F1).
• Footnote F2: The reported amount includes restricted common stock.
• Shares owned after transaction: Not specified in the information provided in your summary filing.

Context
Grants to non-employee directors are common as part of board compensation and do not necessarily signal buying or selling conviction. Because these are restricted shares with multi-year vesting, they are intended to retain the director through future board service rather than provide immediate liquidity.